Achilles Therapeutics PLC (ACHL)
0.8681
+0.01
(+1.43%)
USD |
NASDAQ |
Jun 25, 16:00
0.8681
0.00 (0.00%)
After-Hours: 20:00
Achilles Therapeutics Enterprise Value: -75.25M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | -75.25M |
| June 24, 2024 | -75.77M |
| June 21, 2024 | -75.85M |
| June 20, 2024 | -75.94M |
| June 18, 2024 | -74.10M |
| June 17, 2024 | -73.80M |
| June 14, 2024 | -73.80M |
| June 13, 2024 | -73.59M |
| June 12, 2024 | -73.57M |
| June 11, 2024 | -73.99M |
| June 10, 2024 | -74.53M |
| June 07, 2024 | -73.80M |
| June 06, 2024 | -73.88M |
| June 05, 2024 | -72.20M |
| June 04, 2024 | -73.89M |
| June 03, 2024 | -73.89M |
| May 31, 2024 | -73.03M |
| May 30, 2024 | -72.19M |
| May 29, 2024 | -73.88M |
| May 28, 2024 | -73.03M |
| May 24, 2024 | -73.46M |
| May 23, 2024 | -74.05M |
| May 22, 2024 | -73.89M |
| May 21, 2024 | -72.02M |
| May 20, 2024 | -72.61M |
| Date | Value |
|---|---|
| May 17, 2024 | -71.85M |
| May 16, 2024 | -73.24M |
| May 15, 2024 | -73.03M |
| May 14, 2024 | -73.03M |
| May 13, 2024 | -74.32M |
| May 10, 2024 | -72.18M |
| May 09, 2024 | -73.09M |
| May 08, 2024 | -73.08M |
| May 07, 2024 | -77.05M |
| May 06, 2024 | -76.89M |
| May 03, 2024 | -78.00M |
| May 02, 2024 | -79.01M |
| May 01, 2024 | -78.94M |
| April 30, 2024 | -80.29M |
| April 29, 2024 | -79.87M |
| April 26, 2024 | -79.87M |
| April 25, 2024 | -79.25M |
| April 24, 2024 | -78.85M |
| April 23, 2024 | -78.97M |
| April 22, 2024 | -78.59M |
| April 19, 2024 | -78.89M |
| April 18, 2024 | -78.16M |
| April 17, 2024 | -77.54M |
| April 16, 2024 | -78.06M |
| April 15, 2024 | -77.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-157.05M
Minimum
May 09 2022
566.38M
Maximum
Apr 06 2021
-56.67M
Average
-100.81M
Median
Enterprise Value Benchmarks
| Barinthus Biotherapeutics PLC | -75.92M |
| TC BioPharm (Holdings) PLC | 2.372M |
| Adaptimmune Therapeutics PLC | 77.49M |
| Biodexa Pharmaceuticals Plc | 0.2994M |
| Verona Pharma PLC | 1.013B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.27M |
| Total Expenses (Quarterly) | 14.30M |
| EPS Diluted (Quarterly) | -0.30 |
| Earnings Yield | -184.3% |